139 related articles for article (PubMed ID: 17087058)
1. [Antiviral etiotropic chemicals: efficacy against influenza A viruses A subtype H5N1].
Leneva IA; Shuster AM
Vopr Virusol; 2006; 51(5):4-7. PubMed ID: 17087058
[TBL] [Abstract][Full Text] [Related]
2. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
[TBL] [Abstract][Full Text] [Related]
3. [Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models].
Leneva IA; Fediakina IT; Eropkin MIu; Gudova NV; Romanovskaia AA; Danilenko DM; Vinogradova SM; Lepeshkin AIu; Shestopalov AM
Vopr Virusol; 2010; 55(3):19-27. PubMed ID: 20608077
[TBL] [Abstract][Full Text] [Related]
4. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
Nguyen JT; Smee DF; Barnard DL; Julander JG; Gross M; de Jong MD; Went GT
PLoS One; 2012; 7(1):e31006. PubMed ID: 22292088
[TBL] [Abstract][Full Text] [Related]
6. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
7. The combination of ribavirin and ozeltamivir effectively inhibits reproduction of influenza A virus resistant to rimantadine (amantadine) in vitro and in vivo.
Deryabin PG; Galegov GA; Konstantinova ID; Muzyka IS; Miroshnikov AI; L'vov DK
Dokl Biochem Biophys; 2014 Mar; 455(1):80-3. PubMed ID: 24795106
[No Abstract] [Full Text] [Related]
8. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.
Leneva IA; Goloubeva O; Fenton RJ; Tisdale M; Webster RG
Antimicrob Agents Chemother; 2001 Apr; 45(4):1216-24. PubMed ID: 11257037
[TBL] [Abstract][Full Text] [Related]
11. Antivirals and influenza: frequency of resistance.
Monto AS
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
[TBL] [Abstract][Full Text] [Related]
12. Influenza virus inhibitors available for the chemotherapy and/or chemoprophylaxis of influenza virus infections.
De Clercq E
Verh K Acad Geneeskd Belg; 2006; 68(2):121-37. PubMed ID: 16800242
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
[TBL] [Abstract][Full Text] [Related]
14. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Hurt AC; Lowther S; Middleton D; Barr IG
Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
[TBL] [Abstract][Full Text] [Related]
15. Antiviral management of seasonal and pandemic influenza.
Hayden FG; Pavia AT
J Infect Dis; 2006 Nov; 194 Suppl 2():S119-26. PubMed ID: 17163384
[TBL] [Abstract][Full Text] [Related]
16. Insights into inflammation and influenza.
Simmons C; Farrar J
N Engl J Med; 2008 Oct; 359(15):1621-3. PubMed ID: 18843127
[No Abstract] [Full Text] [Related]
17. Neuraminidase inhibitor resistance in influenza viruses.
Reece PA
J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
[TBL] [Abstract][Full Text] [Related]
18. [In vitro effects of antiviral drugs on the reproduction of highly pathogenic influenza A/H5N1 virus strains that induce epizooty among poultry in the summer of 2005].
L'vov DK; Fediakina IT; Shchelkanov MIu; Prilipov AG; Deriabin PG; Galegov GA
Vopr Virusol; 2006; 51(2):20-2. PubMed ID: 16756173
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of the antiviral activity of 2HCl*H-His-Rim compound compared to the anti-influenza drug Arbidol for influenza caused by A/duck/Novosibirsk/56/05 (H5N1) (Influenza A virus, Alphainfluenzavirus, Orthomyxoviridae).].
Deryabin PG; Garaev TM; Finogenova MP; Odnovorov AI
Vopr Virusol; 2019; 64(6):268-273. PubMed ID: 32168440
[TBL] [Abstract][Full Text] [Related]
20. [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A].
Leneva IA; Fediakina IT; Gus'kova TA; Glushkov RG
Ter Arkh; 2005; 77(8):84-8. PubMed ID: 16206613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
